Ontology highlight
ABSTRACT:
SUBMITTER: Miyake T
PROVIDER: S-EPMC7891601 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
Miyake Takeshi T Kimoto Emi E Luo Lina L Mathialagan Sumathy S Horlbogen Lauren M LM Ramanathan Ragu R Wood Linda S LS Johnson Jillian G JG Le Vu H VH Vourvahis Manoli M Rodrigues A David AD Muto Chieko C Furihata Kenichi K Sugiyama Yuichi Y Kusuhara Hiroyuki H
Clinical pharmacology and therapeutics 20201009 2
Endogenous biomarkers are emerging to advance clinical drug-drug interaction (DDI) risk assessment in drug development. Twelve healthy subjects received a multidrug and toxin exclusion protein (MATE) inhibitor (pyrimethamine, 10, 25, and 75 mg) in a crossover fashion to identify an appropriate endogenous biomarker to assess MATE1/2-K-mediated DDI in the kidneys. Metformin (500 mg) was also given as reference probe drug for MATE1/2-K. In addition to the previously reported endogenous biomarker ca ...[more]